Certipharm
Turnover is estimated at about €190,000, probably between €150,000 and €260,000. The micro format does not state turnover.
Balance sheet
balance sheet total €157,372 on 31-12-2025in euro
in euro
Position in the sector
65.3%
Higher than 64% of the 10,299 companies filing micro accounts in office administrative support (NACE 82) in 2025.
2.85
Higher than 64% of the 9,879 companies filing micro accounts in office administrative support (NACE 82) in 2025.
58.3%
Higher than 92% of the 10,021 companies filing micro accounts in office administrative support (NACE 82) in 2025.
Net result: top quarter · Equity: middle half · Balance sheet total: middle half · Working capital: top quarter
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 202115 months |
|---|---|---|---|---|---|---|
| 123,793 | 84,706 | 138,920 | 105,198 | 150,579 | ||
| 92,217 | 59,633 | 109,546 | 84,732 | 118,328 | ||
| 869 | 0 | 0 | 2,644 | 17,000 | ||
| 89,636 | -223,664 | 80,111 | 77,949 | - | ||
| 101,015 | 59,666 | 293,962 | 185,416 | 103,328 | ||
| 65.3% | 93.6% | 93.2% | 91.2% | 83.7% | ||
| 2.85 | 15.32 | 14.64 | 10.95 | 5.60 | ||
| 0.53 | 0.07 | 0.07 | 0.10 | 0.19 | ||
| 89.2% | 96.7% | 35.3% | 40.0% | 98.3% | ||
| 58.3% | 90.6% | 32.9% | 36.5% | 82.3% | ||
| over 100 | over 100 | over 100 | over 100 | over 100 |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 202115 months |
|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||
20/58 |
157,372 | 65,270 | 317,485 | 211,223 | 138,033 | |
21/28 |
1,778 | 1,438 | 1,966 | 7,164 | 12,225 | |
22/27 |
1,778 | 1,438 | 1,966 | 7,164 | 12,225 | |
24 |
1,778 | 1,438 | 1,966 | 7,164 | 12,225 | |
29/58 |
155,594 | 63,833 | 315,519 | 204,059 | 125,808 | |
40/41 |
18,983 | 15,560 | 44,112 | 12,552 | 13,229 | |
40 |
18,983 | 15,560 | 44,112 | 7,950 | 13,229 | |
41 |
- | - | 0 | 4,602 | - | |
54/58 |
136,612 | 46,976 | 270,640 | 190,528 | 112,579 | |
490/1 |
- | 1,297 | 767 | 978 | - | |
| Balance sheet: equity and liabilities | ||||||
10/49 |
157,372 | 65,270 | 317,485 | 211,223 | 138,033 | |
10/15 |
102,793 | 61,104 | 295,929 | 192,580 | 115,552 | |
10/11 |
2,000 | 2,000 | 2,000 | 2,000 | 2,000 | |
13 |
100,793 | 59,104 | 293,929 | 190,580 | 113,552 | |
133 |
100,793 | 59,104 | 293,929 | 190,580 | 113,552 | |
14 |
- | - | 0 | - | - | |
17/49 |
54,580 | 4,166 | 21,557 | 18,643 | 22,481 | |
42/48 |
54,580 | 4,166 | 21,557 | 18,643 | 22,481 | |
44 |
127 | - | 487 | 2,254 | 1,308 | |
440/4 |
127 | - | 487 | 2,254 | 1,308 | |
45 |
3,593 | 3,987 | 19,647 | 15,875 | 20,508 | |
450/3 |
3,593 | 3,987 | 19,647 | 15,875 | 20,508 | |
47/48 |
50,859 | 179 | 1,422 | 514 | 665 | |
| Income statement | ||||||
9900 |
124,569 | 85,612 | 139,092 | 105,362 | 150,680 | |
630 |
529 | 529 | 5,198 | 7,704 | 4,775 | |
640/8 |
776 | 906 | 172 | 164 | 101 | |
9901 |
123,264 | 84,177 | 133,722 | 97,494 | 145,804 | |
75/76B |
0 | - | - | - | - | |
75 |
0 | - | - | - | - | |
65/66B |
70 | 73 | 69 | 69 | 74 | |
65 |
70 | 73 | 69 | 69 | 74 | |
9903 |
123,194 | 84,104 | 133,653 | 97,425 | 145,730 | |
67/77 |
31,505 | 25,000 | 29,305 | 20,397 | 32,177 | |
9904 |
91,689 | 59,104 | 104,348 | 77,028 | 113,552 | |
9905 |
91,689 | 59,104 | 104,348 | 77,028 | 113,552 | |
| Appropriation of the result | ||||||
9906 |
91,689 | 59,104 | 104,348 | 77,028 | 113,552 | |
791/2 |
- | 293,929 | - | - | - | |
691/2 |
41,689 | 59,104 | 103,348 | 77,028 | 113,552 | |
6921 |
41,689 | 59,104 | 103,348 | 77,028 | 113,552 | |
694/7 |
50,000 | 293,929 | 1,000 | - | - | |
694 |
50,000 | 293,929 | 1,000 | - | - | |
| Document | ||||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 14-08-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankThe accounts were filed on 14-08-2026. The deadline was 31-07-2026, 7 months after the close on 31-12-2025 (article 3:10 of the Companies and Associations Code). Source: NBB, 2026-00398573.
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 14-08-2026 | 2026-00398573 | |
| 31-12-2024 | micro format | 18-08-2025 | 2025-00380279 | |
| 31-12-2023 | micro format | 26-02-2024 | 2024-00035445 | |
| 31-12-2022 | micro format | 31-07-2023 | 2023-00293397 | |
| 31-12-2021 | micro format | 26-07-2022 | 2022-20221121 |
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | €869 | - | - | €2,644 | €17,000 |
| €529 | €529 | €5,198 | €7,704 | €4,775 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on Certipharm
The operating result for 2025 is 46% higher than in 2024. It is a recovery after the fall in 2024.
Debt's share of the balance-sheet total rises from 6.4% to 34.7%. Equity and debt are higher.